Abstract: Methods for preventing corrosion and scale deposition in aqueous media are disclosed. The methods utilize water-soluble polymers having pendant derivatized amide functionalities for scale inhibition.

Abstract: Methods for dispersing and binding ceramic materials in aqueous media are disclosed. The methods utilize water-soluble polymers having pendant derivatized amide, ester or ether functionalities for dispersing and binding various classes of ceramic materials.

Abstract: Disclosed are the Rhodamine B esters of hydroxy C.sub.2 -C.sub.6 lower alkyl acrylates. Specifically, the hydroxy lower alkyl radical is a linear hydroxy lower alkyl radical having the hydroxy group attached to the terminal carbon atom. Also shown are copolymers of diallyldimetyl ammonium chloride which contains from 0.01-2 mole percent of these Rhodamine B esters and their use in treating industrial waters.

Abstract: Zwitterionic water-soluble imine corrosion inhibitors of the general formula: ##STR1## wherein R.sup.3 is an anionically charged group. Preferred zwitterionic imines are the reaction products of the Michael addition of acrylic acid to an imine.

Abstract: A gelling agent for viscosifying liquid hydrocarbon fracturing fluids is an aluminum salt of a phosphate ester made by forming the ester by reacting P.sub.2 O.sub.5 with a mixture of organic alcohols which include high molecular weight alcohols or diols selected from hydroxy functional homopolymers, copolymer or terpolymer made from olefins and diolefins selected from the group consisting of ethylene, propylene, butene, butadiene, isoprene, and selected styrenes. The oil based fracturing fluid containing the gelling agent in sufficient concentration to provide a viscosity of between 50 cp and 350 cp at 100.degree. F.

Abstract: This invention relates to inhibiting corrosion in systems of condensing hydrocarbons which contain water and chlorides, and, more particularly, in the overhead of crude oil atmospheric pipestills, with blends of amines. Preferred blends are 2-amino-1-methoxypropane, sec-butylamine, n-butylamine, dipropylamine and monoamylamine; 2-amino-1-methoxypropane, sec-butylamine, monoamylamine, n-butylamine and isobutylamine; and sec-butylamine, 2-amino-1-methoxypropane and 3-amino-1-methoxypropane.

Abstract: A method of inhibiting corrosion of iron and steel alloys in contact with oil-in-brine emulsions is claimed. The method comprises treating the oil-in-brine emulsions with an effective amount of a water soluble polymer having an average molecular weight of at least one million and an effective amount of a nitrogen-containing corrosion inhibitor.

Abstract: Hydrophilic cationic copolymers of acrylamide are prepared as dispersions in a salt media. These polymers have high molecular weights and are readily soluble by diluting in water. These polymers are useful flocculants for such applications as sludge dewatering, raw water clarification aids, emulsion breakers and waste water clarification aids.

Abstract: The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.

Abstract: Novel farnesyl transferase inhibitors of general formula (I) ##STR1## preparation thereof and pharmaceutical compositions containing same. In general formula (I), R.sub.1 is Y--S--A.sub.1 -- (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical, or a radical R.sub.4 --S--, where R.sub.4 is a C.sub.1-6 alkyl radical optionally substituted by a phenyl radical, or a radical of general formula (II), ##STR2## wherein A.sub.1, X.sub.1, Y.sub.1, R'.sub.2, R'.sub.2, X.sub.2, Y.sub.2, R.sub.3, R'.sub.3 and R are as defined below, and A.sub.1 is a C.sub.1-4 alkylene radical optionally .alpha.-substituted in the >C(X.sub.1) (Y.sub.1) grouping by an amino, alkylamino, alkanoylamino or alkoxycarbonylamino radical); X.sub.1 and Y.sub.1 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, a >C.dbd.O grouping; R.sub.2 is a straight or branched C.sub.1-4 alkyl radical optionally substituted by a cyclohexyl radical; R'.sub.

Abstract: A Chrysosporium strain No. CBS 123.95, mutants and derivatives thereof, and a method for preparing non-peptide compounds using said strain, are disclosed. Novel compounds of general formula (I), pharmaceutical compositions containing same, and the use of said compounds in anticancer treatments, are also disclosed.

Abstract: The invention is directed to a compound of formula ##STR1## in which R represents a hydroxyl, alkyloxy, phenylalkyloxy or --NH--CH.sub.2 --COOH radical, R.sub.1 represents a hydrogen atom, an adamantylacetyl, adamantylcarbonyl, norbornylacetyl, norbornylphenoxycarbonyl, benzoyl, nicotinoyl, 4-phenylbenzoyl, 4-tert-butylbenzoyl or 2-pyrrolidinecarbonyl radical or a protective group for an amine functional group, R.sub.2 represents an Arg or Lys residue, R.sub.3 represents an Arg or Lys residue, R.sub.4 represents a Pro residue, m, n and p, which are the identical or different, represent a number equal to 0 or 1, R.sub.5 and R.sub.6 are identical and represent a hydroxyl or methoxy radical and R.sub.7 represents a hydrogen, chlorine, bromine or iodine atom or a nitro radical, or the compound wherein one or a number of peptide bonds between two amino acid residues are replaced by --CH.sub.2 --NH bonds or the peptide bond between the R.sub.2 and R.sub.3 amino acid residues is replaced by a CH.dbd.

Abstract: Compounds of formula I ##STR1## where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, and are as defined herein, their use as antiinflammatory, immunosuppressive, and antiallergic agents, pharmaceutical compositions comprising them, and methods for their preparation comprising irradiating compounds of formula II ##STR2## under an inert atmosphere, in the presence or absence of a compound of formula R.sub.3 --S--S(O).sub.m --R.sub.8, where R.sub.7, R.sub.8, and m are as defined herein, and methods for their preparation comprising oxidizing, reducing, halogenating, or alkylating compounds of formula I are disclosed.

Abstract: The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-?N-?N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl!-(L)-aspartyl!-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.

Abstract: Novel farnesyl transferase inhibitors of general formula (I) ##STR1## preparation thereof and pharmaceutical compositions containing same. In general formula (I), R.sub.1 is Y--S--A.sub.1 -- (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, or an alkyl or alkoxycarbonyl radical, and A.sub.1 is a C.sub.1-4 alkylene radical optionally .alpha.-substituted in the >C(X.sub.1) (Y.sub.1,) grouping by an amino, alkylamino, alkanoylamino or alkoxycarbonylamino radical wherein the alkyl or alkanoyl portion contains 1-6 carbon atoms; each of X.sub.1 and Y.sub.1 is a hydrogen atom or X.sub.1 and Y.sub.1, taken toether with the carbon atom to which they are attached, form a >C.dbd.O grouping; R'.sub.1 is hydrogen or a C.sub.1-6 alkyl radical; X is an oxygen or sulphur atom; R.sub.2 is a C.sub.1-6 alkyl, alkenyl or alkynyl radical optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl.

Abstract: The invention is directed to a novel compound of formula ##STR1## in which R is a hydroxyl, alkyloxy, phenylalkyloxy or --NH--CH.sub.2 --COOH radical, R' and R" are identical and are each a hydroxy or methoxy radical and R'" represents a hydrogen, bromine, chlorine or iodine atom or a nitro radical. The invention is also directed to the salts of said compounds and their use.

Abstract: A Steptomyces No. CBS 154.94 strain, mutants or derivatives thereof, and a method for preparing peptides using said strain, are disclosed. Novel peptides of general formula (1), pharmaceutical compositions containing same, and the use thereof in cancer therapy, are also disclosed.

Abstract: The invention relates to new mixtures of sulfated oligosaccharides having the general structure of heparin constitutive oligosaccharides, having an average molecular mass of 6.+-.0.6 kD, a polydispersiveness close to 1 and the capacity of inhibiting the production of thrombin. The invention also relates to their preparation and to pharmaceutical compositions containing them.

Abstract: The invention relates to new mixtures of sulfated oligosaccharides having the general structure of heparin constitutive oligosaccharides, having an average molecular mass of 6.+-.0.6 kD, a polydispersiveness close to 1 and the capacity of inhibiting the production of thrombin. The invention also relates to their preparation and to pharmaceutical compositions containing them.

Abstract: A method according to the invention is directed to the preparation of a 2-azadihydroxybicyclo?2.2.1!heptane compound of formula ##STR1## wherein * represents an R chirality, *' represents an S chirality, R is hydrogen or, respectively, a group of formula ##STR2## wherein R.sub.1 is alkyl and Ar is optionally substituted aryl, comprising bishydroxylating a bicyclo?2.2.1!heptene compound of formula ##STR3## wherein *, *' and R are as previously defined, in the presence of about 0.1 mol to about 5 mol % of a metal osmate compound or about 0.06 mol % to about 0.07 mol % osmium tetroxide, and an oxidizing agent capable of regenerating osmium tetroxide.The invention is also directed to the treatment of the (1R) diastereomer of the 2-azadihydroxybicyclo?2.2.1!heptane compound (I) wherein R is a group of formula II with L-tartaric acid, and the L-tartaric acid salt product thereof. Furthermore, the invention is directed to using the (1R) diastereomer of the 2-azadihydroxybicyclo?2.2.